Drug-delivery systems of phytochemicals as therapeutic strategies in cancer therapy

Authors

Akhileshwar Kumar Srivastava CSIR-Central Food Technological Research Institute, Mysore, India. Dr. Akhileshwar Kumar Srivastava works as a Research Associate (ICMR) in CSIR-Central Food Technological Research Institute, Mysore, India. In his eight years of research, he has published approximately 20 research articles and book chapters in international and national journals of repute. His research specialization is primarily in the area of pharmacognosy with genetics, metabolomics, bioinformatics, and molecular biology-associated targeting cancer diseases. In addition, he has studied at Augusta University (formerly, Georgia Regents University) in Augusta, GA, United States on a J-1 Exchange Scholar Visa and at Ben-Gurion University, Israel. He is also a life member fellow in Indian Science Congress and Agriculture, Nutrition and Health Academy, United Kingdom. Divya Singh CSRTI. Divya Singh is presently working as Scientist-B in Department of Mulberry Physiology, CSRTI, Mysore, India. Her research specialization is primarily in genetics, proteomics, metabolomics, toxicology, bioinformatics and molecular biological evaluation in various in vivo and in vitro plant models to elucidate the physiological changes and evaluate the DNA damage potency. In her 11 years of research experiences, she has published 8-peer reviewed publications, two books (1 edited and 1 authored) including 6 book chapters and several meeting presentations at local and international scientific meetings. Rajesh Kumar Singh Research Associate, Centre of Experimental Medicine and Surgery at Banaras Hindu University, India. Dr. Rajesh Kumar Singh is currently working as a Research Associate in Banaras Hindu University. His research focus is pharmacognosy, reverse pharmacology, drug design and discovery, extraction & isolation of natural products, cell culture, and handling of different rodents. He has published several research articles in reputable journals over the course of his career. At present, he is involved in developing an Indian origin cell line and screening drugs of natural origin for the treatment of gallbladder cancer.